Globalization and access to biotechnology-derived health care products: a view from Egypt.

Eldawy, M. A.; Serageldin, I.; Persley, G. J.

doi:10.1079/9780851996752.0191

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As biosimilars continue to enter the Egyptian pharmaceutical market, they not only offer huge cost savings for patients, physicians, insurance providers, and governments, but also add to the physician's list of treatments available for a variety of diseases. 9,10 Several studies have concluded that biosimilar epoetin-α is the most cost-effective erythropoiesisstimulating agent available for managing chemotherapyinduced anemia using both fixed and weight-based dosing strategies. Using fixed-dosing scenarios, the average cost savings associated with use of biosimilar epoetin-α 40,000 IU ranged from €990 (13.8%) to €3,042 (33.0%), while for biosimilar epoetin-α 30,000 IU the average savings ranged from €2,534 (35.4%) to €4,587 (49.7%).…”

Section: Biosimilars 10 May 2014 Number Of Times This Article Has Beementioning

confidence: 99%

Production and analysis of a biosimilar erythropoietin in Egypt

Ebied¹,

Ahmed²,

Elbarbry³

2014

View full text Add to dashboard Cite

Although management of chronic diseases has been a major challenge for health care systems in developed and developing countries, biopharmaceuticals have been successful in treating many life-threatening conditions. However, the high cost of these agents restricts their availability to countries where patients and/or health care systems are able to afford them. Licensing these biopharmaceuticals as biosimilars after expiration of their patents might increase access to such medicines at an affordable price in developing countries. South Egypt Drug Industries Company (SEDICO) is an Egyptian pharmaceutical company that has had the opportunity to manufacture some of these drugs. SEDICO biotechnology products, such as insulin, erythropoietin, streptokinase, angiokinase, follicle-stimulating hormone, aprotinin, filgrastim, and somatropin, have been available on the Egyptian market for more than 6 years. For this paper, erythropoietin, which has been investigated over a number of years, was chosen as a representative example of SEDICO biotechnology products. Our findings confirm that SEDICO erythropoietin can compete with the originator epoetins on the Egyptian market with high quality and at a lower cost.

show abstract

Section: Biosimilars 10 May 2014 Number Of Times This Article Has Beementioning

confidence: 99%